Sarah Smedley writes the FDA Watch column for MedShadow. She has 20 years experience in communications for the medical, pharmaceutical, biotech, consumer health, fitness, philanthropy and nutrition industries. She is now a freelance writer and a contributor to The Broadsheet, a daily online and bi-weekly print newspaper. Sarah also served as communications liaison for the Black AIDs Institute during the XIX International AIDS Conference in 2013. She has a Bachelor of Art degree from Wesleyan University, and did post graduate work at Lehigh University and George Washington
If you’re like most people, you’ve played the laboratory test waiting game, anticipating results that could tell if you have a serious illness or not. As if this wasn’t nerve wracking enough, ...
February 15, 2016 - 7:01am
With all the talk about personalized medicine, one would think that clinical drug trials would address the differences between the sexes. Unfortunately, that’s not always the case.
Before a ...
November 26, 2015 - 10:24am
I am dismayed at the FDA’s approval of Addyi (flibanserin) the first drug to treat low sex desire in pre-menopausal women.
To call this new drug the “Pink Viagra” is not medically accurate. ...
August 26, 2015 - 11:21am